Results 21 to 30 of about 70,439 (302)

Levodopa-responsive chorea: A review

Annals of Indian Academy of Neurology, 2020
Background: Chorea is one of the disabling movement disorders, and the number of drugs which can treat this disorder effectively is limited. Tetrabenazine and deutetrabenazine are the two drugs approved by the US-FDA for the treatment of chorea ...
Mark Farrenburg, Harsh V Gupta
doaj   +1 more source

Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase

npj Parkinson's Disease, 2021
Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed
Anouke van Rumund, Lukas Pavelka, Rianne A. J. Esselink, Ben P. M. Geurtz, Ron A. Wevers, Brit Mollenhauer, Rejko Krüger, Bastiaan R. Bloem, Marcel M. Verbeek   +8 more
doaj   +1 more source

Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. [PDF]

, 2019
ObjectiveTo understand the safety, putaminal coverage, and enzyme expression of adeno-associated viral vector serotype-2 encoding the complementary DNA for the enzyme, aromatic L-amino acid decarboxylase (VY-AADC01), delivered using novel intraoperative ...
Bankiewicz, Krystof S, Boot, Brendon, Christine, Chadwick W, Kells, Adrian P, Larson, Paul S, Martin, Alastair J, Nutt, John, Ravina, Bernard, Richardson, R Mark, Thompson, Marin E, Van Laar, Amber D   +10 more
core   +1 more source

Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. [PDF]

, 2014
Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms resulting from aberrant plasticity changes in the human brain.
Ahmed, Ananth, Aron, Aron, Baldessarini, Breakefield, Brooks, Byl, Calabresi, Calabresi, Carta, Casey, Casey, Castrén, Cenci, Cenci, Cerasa, Cerasa, Cerasa, Cerasa, Cerasa, Clarke, Crow, Crow, de la Fuente-Fernandez, de la Fuente-Fernandez, Fahn, Ganos, Gottwald, Heckers, Jankovic, Jellinger, Jenner, Kishore, Kishore, Koch, Koch, Koch, Li, Marsden, McEwen, Morgante, Nambu, Obeso, Pakkenberg, Peralta, Picconi, Quartarone, Rascol, Rylander, Salgado-Pineda, Sawada, Sgambato-Faure, Sigwald, Spencer, Teo, Vernon, Vernon, Zesiewicz   +58 more
core   +2 more sources

Exploring the levodopa-paradox of freezing of gait in dopaminergic medication-naïve Parkinson’s disease populations

npj Parkinson's Disease, 2023
The relationship between dopaminergic treatment and freezing of gait (FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an ...
Jamie A. F. Jansen, Tamine T. C. Capato, Sirwan K. L. Darweesh, Egberto R. Barbosa, Rogier Donders, Bastiaan R. Bloem, Jorik Nonnekes   +6 more
doaj   +1 more source

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients

Cells, 2022
The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.
Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede   +3 more
doaj   +1 more source

Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis [PDF]

, 2010
Background/Aims: Increasing evidence suggests that elevated levels of homocysteine (Hcy) and methylmalonate (MMA) may be involved in the pathogenesis of neurodegenerative diseases. Methods: The urine levels of MMA and serum levels of Hcy as well as folic
Bötzel, Kai, Giese, Armin, Levin, Johannes, Lorenzl, Stefan, Vogeser, Michael   +4 more
core   +1 more source

Experience in using levodopa-benserazide

Неврология, нейропсихиатрия, психосоматика, 2015
Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications.
Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova   +3 more
doaj   +1 more source

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease

Frontiers in Neurology, 2021
Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of
Natalia Palacios, Natalia Palacios, Natalia Palacios, Anas Hannoun, Julie Flahive, Doyle Ward, Doyle Ward, Kelsey Goostrey, Anindita Deb, Kara M. Smith   +9 more
doaj   +1 more source

Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes

Frontiers in Neurology, 2021
Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of ...
Xin-yao Li, Ying-mai Yang, Li-bo Li, Meng-yu Zhang, Yang-yu Huang, Jie Wang, Lin Wang, Xin-hua Wan   +7 more
doaj   +1 more source